Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to SOC in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring Below the Distal Border of the Brachial Plexus Requiring Surgical Repair.
Latest Information Update: 25 Nov 2024
At a glance
- Drugs NTX-001 Neuraptive Therapeutics (Primary)
- Indications Peripheral nerve injuries
- Focus Adverse reactions; Therapeutic Use
- Acronyms Trauma study
- Sponsors Neuraptive Therapeutics
Most Recent Events
- 18 Nov 2024 Status changed from active, no longer recruiting to completed.
- 14 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Planned End Date changed from 15 Jun 2023 to 15 Aug 2024.